Roche (OTCMKTS:RHHBY) Upgraded to Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Roche (OTCMKTS:RHHBYGet Rating) from a hold rating to a buy rating in a research report report published on Thursday, The Fly reports.

RHHBY has been the topic of a number of other reports. Credit Suisse Group dropped their price target on Roche from CHF 370 to CHF 350 and set a neutral rating on the stock in a research note on Thursday, May 19th. Cowen dropped their price target on Roche from $58.00 to $48.00 and set an outperform rating on the stock in a research note on Monday, June 27th. Morgan Stanley dropped their price target on Roche from CHF 370 to CHF 350 and set an equal weight rating on the stock in a research note on Wednesday. Deutsche Bank Aktiengesellschaft dropped their price target on Roche from CHF 350 to CHF 325 and set a hold rating on the stock in a research note on Friday, July 22nd. Finally, Cowen dropped their price target on Roche from $58.00 to $48.00 and set an outperform rating on the stock in a research note on Monday, June 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Hold and an average target price of $260.14.

Roche Stock Performance

Shares of Roche stock opened at $41.76 on Thursday. Roche has a one year low of $37.88 and a one year high of $53.86. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.73 and a current ratio of 0.93. The stock’s 50-day moving average is $41.55 and its 200 day moving average is $44.06.

Hedge Funds Weigh In On Roche

Several institutional investors have recently modified their holdings of RHHBY. Sofinnova Investments Inc. bought a new position in shares of Roche in the fourth quarter valued at approximately $70,764,000. Fisher Asset Management LLC grew its holdings in shares of Roche by 25.0% in the first quarter. Fisher Asset Management LLC now owns 5,823,906 shares of the company’s stock valued at $289,890,000 after acquiring an additional 1,165,391 shares in the last quarter. Cardinal Capital Management Inc. bought a new position in shares of Roche in the first quarter valued at approximately $18,402,000. Todd Asset Management LLC grew its holdings in shares of Roche by 114.6% in the second quarter. Todd Asset Management LLC now owns 592,706 shares of the company’s stock valued at $24,722,000 after acquiring an additional 316,509 shares in the last quarter. Finally, Saratoga Research & Investment Management grew its holdings in shares of Roche by 26.1% in the second quarter. Saratoga Research & Investment Management now owns 1,366,826 shares of the company’s stock valued at $57,010,000 after acquiring an additional 283,119 shares in the last quarter. 0.23% of the stock is owned by institutional investors.

Roche Company Profile

(Get Rating)

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.

See Also

The Fly logo

Analyst Recommendations for Roche (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.